<DOC>
	<DOCNO>NCT01598454</DOCNO>
	<brief_summary>This study carry child diagnosis cancer tumor know express N-glycolylated gangliosides . The disease must resistant conventional therapy . The acute toxicity immune response evaluate . The expression N-glycolylated gangliosides tumor previously investigate tumor sample bank Hospital . The expression N-glycolyl GM3 show neuroblastoma , Ewing 's sarcoma , Wilm 's tumor retinoblastoma . Gliomas aforementioned tumor type bad prognosis conventional treatment ineffective . New therapeutic strategy thus examine , several immunotherapeutic approach , include dendritic cell vaccine , peptide vaccine anti-idiotype vaccine currently assess . Racotumomab anti-idiotype antibody capable induce anti-N-glycolyl GM3 antibody patient melanoma , breast cancer lung cancer . Dose escalation study show safety racotumomab 0.5 2 mg dose range . The 1 mg dose level select ensue clinical study . This clinical trial child involve three dose level : 0.15 mg , 0.25 mg 0.4 mg , owe difference body surface adult ( 1.73 sq . average ) candidate population study ( 0.55 0.7 sq . ) .</brief_summary>
	<brief_title>Use Racotumomab Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Children ( gender ) 1 10 year old time accrual . Diagnosis neuroblastoma ( progression first line treatment ) , glioma ( progress disease metastatic disease , without curative treatment option ) , Ewing 's sarcoma ( progressive metastatic disease first line treatment progressive disease second line treatment ) , Wilm 's tumor ( metastatic relapse treatment ) , retinoblastoma ( progress disease metastatic relapse first line treatment ) . Previous cancer treatment finish 30 day accrual . Lansky performance status 50 . History encephalopathy , convulsion , asthma severe allergy . Infectious disease grade 3 4 accord CTCAE version 3 . Hepatic , kidney cardiac insufficiency . Marrow insufficiency selftransplantation hematopoietic stem cell . Weight inferior 12 kg time accrual . Concomitant cancer treatment . Inability comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>